Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by wexworthon Nov 13, 2020 3:03pm
113 Views
Post# 31896739

RE:RE:Posted message german board

RE:RE:Posted message german board
then how do you explain why we went from mid twenties up to 34 cents when early speculation was that a rodan launch was imminent in October? if it had of gone, I believe we would be trading in mid 40s, minimum. its more than just a financial statement. In Sirona's case, the product launch, when it happens, that the tap is turned on and I think we are going to be pleasantly surprised at the product volume and market profile we may get...Aurora Cannabis jumped from the 8$ range to $15 in two days over the possibility that Biden would be elected. Then they sh!t their pants and did a public offering at $7.50, only to start climbing back up right away...My point is that the market works on the probability of future earnings and commercial possibility, not just sales next quarter. Its called Value.
Bullboard Posts